Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 7/2017

01.07.2017 | Lung Cancer (JM Johnson, Section Editor)

Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope

verfasst von: Jonathan M. Lehman, Mary E. Gwin, Pierre P. Massion

Erschienen in: Current Oncology Reports | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and “smart bomb”-based drug/radioconjugates have led to good response in early clinical trials. Additionally, new research insights into the genetics and tumor heterogeneity of SCLC alongside the availability of new tools such as patient-derived or circulating tumor cell xenografts offer the potential to shine light on this beshadowed cancer.
Literatur
1.
Codony-Servat J, Verlicchi A, Rosell R. Cancer stem cells in small cell lung cancer. Translational Lung Cancer Research. 2016;5(1):16–25.PubMedPubMedCentral
2.
Sarvi S, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74(5):1554–65.CrossRefPubMed
3.
4.
• Network, N.C.C. NCCN Clinical Practice Guidelines in Oncology Small Cell Lung Cancer Version 2.2017. 2016. September 15, 2016 cited 2016 12/9/2016. Includes clinical recommendations involving immunotherapy treatment in the second-line off study for SCLC for the first time.
5.
• Hodi FS, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology. 2016;17(11):1558–68. Landmark study showing improved efficacy of combination checkpoint inhibitor therapy. CrossRefPubMed
6.
Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.CrossRefPubMed
7.
• Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. Showed for the first time superiority of immunotherapy versus chemotherapy first line in lung cancer. Further supports use of biomarkers, though better biomarkers than PD-L1 alone are needed. CrossRefPubMed
8.
Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 2016;17(11):1497–508.CrossRefPubMed
9.
Lowenbraun S, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer. 1979;44(2):406–13.CrossRefPubMed
10.
Chute JP, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17(6):1794.CrossRefPubMed
11.
Sundstrøm S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665–72.CrossRefPubMed
12.
13.
Pieczonka CM, et al. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: considerations for clinical practice. Reviews in Urology. 2015;17(4):203–10.PubMedPubMedCentral
14.
Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc. 2009;6(2):224–32.CrossRefPubMed
15.
16.
• Carter L, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2016. advance online publication. Exciting association with CDXs and correlation with patient profiles and chemoresponsiveness. This brings this model forward and could help lead to better personalized medicine and SCLC modeling.
17.
Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561–84.CrossRefPubMed
18.
Kvistborg P, et al. Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254ra128.CrossRefPubMed
19.
Wang W, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells. Int Immunol. 2009;21(9):1065–77.CrossRefPubMedPubMedCentral
20.
•• Antonia SJ, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology. 2016;17(7):883–95. Still preliminary but exciting data for efficacy, particularly in combination for SCLC. This study needs further confirmation but opens the door for immunotherapy to change the clinical treatment of SCLC. CrossRefPubMed
21.
• Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. Practice-changing trial along with #23, brought immunotherapy to lung cancer. CrossRefPubMed
22.
Garon EB, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.CrossRefPubMed
23.
Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMed
24.
•• George J, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. Together, these two articles have brought SCLC into the genetic age with sequencing of 100+ primary SCLC samples and RNAseq. The studies need to be expanded with clinically annotated samples, but these studies built the foundation that is needed to move forward with genetic characterization of this disease.
25.
•• Rudin CM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–6. Together, these two articles have brought SCLC into the genetic age with sequencing of 100+ primary SCLC samples and RNAseq. The studies need to be expanded with clinically annotated samples, but these studies built the foundation that is needed to move forward with genetic characterization of this disease. CrossRefPubMedPubMedCentral
26.
27.
• Thomas LR, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015;58(3):440–52. Novel targeting approach for MYC, which is an extremely challenging target and vital for SCLC as well as multiple other tumor types. CrossRefPubMedPubMedCentral
28.
Paolo Fiorentino F, et al. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget. 2016;7(21):31014–28.
29.
Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene. 2015;34(5):537–45.CrossRefPubMed
30.
Glover DM, et al. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 1995;81(1):95–105.CrossRefPubMed
31.
Schoffski P, et al. Efficacy and safety of biweekly i.v. administrations of the aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study. Ann Oncol. 2015;26(3):598–607.CrossRefPubMed
32.
Melichar B, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. The Lancet Oncology. 2015;16(4):395–405.CrossRefPubMed
33.
Helfrich BA, et al. Barasertib (AZD1152), a small molecule aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Mol Cancer Ther. 2016;15(10):2314–22.CrossRefPubMed
34.
Schneider L, et al. Directional cell migration and chemotaxis in wound healing response to PDGF-AA are coordinated by the primary cilium in fibroblasts. Cell Physiol Biochem. 2010;25(2–3):279–92.CrossRefPubMedPubMedCentral
35.
36.
37.
38.
39.
Ezratty EJ, et al. A role for the primary cilium in notch signaling and epidermal differentiation during skin development. Cell. 2011;145(7):1129–41.CrossRefPubMedPubMedCentral
40.
Grisanti L, et al. Primary cilia maintain corneal epithelial homeostasis by regulation of the notch signaling pathway. Development. 2016;143(12):2160–71.CrossRefPubMedPubMedCentral
41.
Mans DA, Voest EE, Giles RH. All along the watchtower: is the cilium a tumor suppressor organelle? Biochim Biophys Acta. 2008;1786(2):114–25.PubMed
42.
Bishop CL, et al. Primary cilium-dependent and -independent hedgehog signaling inhibits p16(INK4A). Mol Cell. 2010;40(4):533–47.CrossRefPubMed
43.
Raleigh D, et al. Hedgehog pathway misactivation induces CDK6 to drive medulloblastoma. International Journal of Radiation Oncology Biology Physics. 2016;96(2):S56.CrossRef
44.
45.
Dere R, et al. β-Catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. J Am Soc Nephrol. 2015;26(3):553–64.CrossRefPubMed
46.
47.
•• Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136. Very strong preclinical data with excellent long-term response in DLL3+ PDX models, followed by clinical trial below. CrossRefPubMedPubMedCentral
48.
• Rudin CM, Pietanza MC, Bauer TM, Spigel DR, Ready N, Morgensztern D, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol. 2016. 34 (suppl; abstr LBA8505). Now in phase II, excited to see full efficacy of this agent, in appropriate high DLL3-expressing SCLC, has a good preliminary response compared to other agents, particularly in refractory DLL3+ disease which has a very poor prognosis otherwise.
49.
Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res. 2016;35(1):179.CrossRefPubMedPubMedCentral
50.
Satoh MS, Lindahl T. Role of poly[ADP-ribose] formation in DNA repair. Nature. 1992;356(6367):356–8.CrossRefPubMed
51.
Murai J, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–43.CrossRefPubMed
52.
53.
Byers LA, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer discovery. 2012;2(9):798–811.CrossRefPubMedPubMedCentral
54.
Pietanza MC, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18(4):1138–45.CrossRefPubMed
55.
Pietanza MC, Krug LM, Waqar SN, Dowlati A, Hann CL, Chiappori A, et al., A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs). J Clin Oncol. 2016. 34 suppl; abstr 8512.
56.
• Cardnell RJ, et al. Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer. PLoS One. 2016;11(4):e0152584. Novel as an example again, that successful use of targeted therapies in SCLC will likely require additional biomarkers. CrossRefPubMedPubMedCentral
57.
Nakajima W, et al. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. in Proceedings of the AACR-IASLC joint conference on molecular origins of lung cancer. 2014. San Diego: AACR.
58.
Perciavalle RM, Opferman JT. Delving deeper: MCL-1’s contributions to normal and cancer biology. Trends Cell Biol. 2013;23(1):22–9.CrossRefPubMed
59.
Langer C, et al. A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). In ASCO annual meeting. 2011. Chicago: ASCO.
60.
Langer C, et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 2014;85(3):420–8.CrossRefPubMed
61.
Nguyen M, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci. 2007;104(49):19512–7.CrossRefPubMedPubMedCentral
62.
• Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–8. This agent’s much higher specificity than obatoclax and better toxicity profile suggest that revising these agents in SCLC may be reasonable. Combination therapy also becomes more feasible with the better side effect profile. CrossRefPubMed
63.
Faber AC, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the Naitonal Academy of Sciences of the United States of America. 2015;112(11):1288–96.CrossRef
64.
Nakajima W, et al. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Cancer Biology & Therapy. 2016;17(1):27–35.CrossRef
65.
Suk Heist R, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010;5(10):1637–43.CrossRef
66.
Baggstrom MQ, et al. A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6(10):1757–60.CrossRefPubMedPubMedCentral
67.
Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.CrossRefPubMed
68.
Peperzak V, et al. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Cell Death Differ. 2016;24(1):111–9. doi:10.​1038/​cdd.​2016.​105.
69.
70.
Ryan J, et al. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397(7):671.CrossRefPubMed
71.
Sharma SK, et al. A DLL3-targeted theranostic for small cell lung cancer: imaging a low density target with a site-specifically modified radioimmunoconjugate. J Nucl Med. 2016;57(supplement 2):50.
72.
• Strosberg J, et al. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-Dotatate: efficacy and safety results. J Nucl Med. 2016;57(supplement 2):629. Landmark PRRT trial in low-grade neuroendocrine tumors. One caveat to comparisons to high-grade neuroendocrine tumors is that imaging may not correlate as closely to SSTR2 expression in SCLC due to inflammatory infiltrate and milieu.
73.
Sollini M, et al. Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients. J Thorac Oncol. 2013;8(8):1095–101.CrossRefPubMed
74.
Lapa C, et al. Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget. 2016;7(15):20033–40.PubMedPubMedCentral
75.
Dalm SU, et al. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med. 2016;57(2):260–5.CrossRefPubMed
76.
Daniel VC, et al. A primary xenograft model of small cell lung cancer reveals irreversible changes in gene expression imposed by culture in-vitro. Cancer Res. 2009;69(8):3364.CrossRefPubMedPubMedCentral
77.
• Anderson WC, et al. Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. PLoS One. 2015;10(5):e0125255. These two papers and previous work with PDXs in SCLC will be vital to overcoming challenges with acquiring sufficient tissue for research. CrossRefPubMedPubMedCentral
78.
• Leong TL, et al. Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens. PLoS One. 2014;9(9):e106862. These two papers and previous work with PDXs in SCLC will be vital to overcoming challenges with acquiring sufficient tissue for research. CrossRefPubMedPubMedCentral
79.
• Rothwell DG, et al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol. 2016;10(4):566–74. Falls into the same theme of broadening available tissue and genetic resources for SCLC. CrossRefPubMedPubMedCentral
80.
Udyavar AR, et al. Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res. 2017;77(5):1063–74. doi:10.​1158/​0008-5472.​can-16-1467.
81.
• Tirosh I, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189–96. Pivotal single cell RNA seq study in cancer. Limited somewhat by efficiency and time required per cell sequence, but the technology and efficiency are improving quickly. CrossRefPubMedPubMedCentral
82.
• Leelatian N, et al. Single cell analysis of human tissues and solid tumors with mass cytometry. Cytometry B Clin Cytom. 2016; First publication with single cell mass cytometry data on SCLC. This technique will allow for characterization of phospho and protein expression at 40+ dimensions at the single cell level in SCLC. This is particularly relevant as is single cell RNAseq given concerns about expression level and epigenetic changes contributing to heterogeneity in SCLC.
Metadaten
Titel
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
verfasst von
Jonathan M. Lehman
Mary E. Gwin
Pierre P. Massion
Publikationsdatum
01.07.2017
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 7/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0609-2

Weitere Artikel der Ausgabe 7/2017

Current Oncology Reports 7/2017 Zur Ausgabe

Breast Cancer (B Overmoyer, Section Editor)

Role of Aspirin in Breast Cancer Survival

Evolving Therapies (R Bukowski, Section Editor)

Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)

Cardio-oncology (EH Yang, Section Editor)

Cardiac Amyloidosis: Diagnosis and Treatment Strategies

Gynecologic Cancers (NS Reed, Section Editor)

Pediatric Gynecologic Cancers

Gastrointestinal Cancers (J Meyer, Section Editor)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma

Melanoma (RJ Sullivan, Section Editor)

Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen